Phase 2 Lung Cancer Trial, Recruiting NCT05613452 Sponsor: Shanghai Proton and Heavy Ion Center Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Recruiting

NCT05613452
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 80 years old
  • People with a general health and activity level rated as reasonably functional (assessed using a standard medical scoring system called ECOG, scored 0–2)
  • People diagnosed with a type of lung cancer called non-small cell lung cancer (NSCLC), confirmed by a tissue or cell sample, at an early stage (Stage Ia to IIa) that has not spread to lymph nodes or other parts of the body
  • People whose tumor is located at a safe distance from important structures such as the food pipe, main airways, spine, heart, major blood vessels, nerve clusters in the shoulder area, and stomach (at least 2cm away), and at least 1cm from the chest wall
  • People who are not able to have surgery for medical reasons, or who have chosen not to have surgery
  • People whose blood, lung, heart, liver, and kidney function all meet certain minimum levels as determined by test results (confirm specific values with trial site)
  • People who are willing and able to give their signed agreement to participate in the trial

Who may not be able to join:

  • People who have more than one primary tumor
  • People who are unlikely to be able to follow the treatment plan as required
  • People who have another cancer that is currently not under control
  • People whose radiation treatment plan cannot meet the required dose targets or safety limits for surrounding healthy tissue (as assessed by the trial team)
  • People who have previously had radiation therapy to the chest or had radioactive particles implanted in the chest
  • People who have a cardiac pacemaker or other internal metal implants that could be affected by high-energy radiation or could interfere with treatment planning
  • People who are pregnant (confirmed by a blood or urine test) or currently breastfeeding
  • People who are HIV positive, people with an active hepatitis virus infection who need antiviral treatment but cannot receive it due to other health conditions, or people with active syphilis
  • People with a history of mental illness that may make it difficult to complete the treatment
  • People with serious other health conditions that could interfere with radiation therapy, including active infections, recent heart problems such as unstable chest pain or heart attack within the past 6 months, recent hospitalisation for breathing conditions, severely weakened immune function, conditions that cause extreme sensitivity to radiation, or other conditions that the trial team determines may interfere with treatment
  • People whose overall circumstances the treating doctor considers unsuitable for participation in a clinical study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jingfang Mao, PHD, Shanghai Proton and Heavy Ion Center

Phone: 86-21-38296678

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Shanghai Proton and Heavy Ion Center
Registry
ClinicalTrials.gov
Start date
29 September 2024
Est. completion
31 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

disease progression-free survival rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov